isoborneol has been researched along with paclitaxel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graf, H; Klar, U; Röhr, B; Schenk, O; Schulz, H | 1 |
| Chen, T; Dong, X; Li, Y; Ma, H; Meng, X; Qi, D; Su, J; Wang, W; Yang, L; Zhang, X | 1 |
2 other study(ies) available for isoborneol and paclitaxel
| Article | Year |
|---|---|
New synthetic inhibitors of microtubule depolymerization.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopolymers; Camphanes; Drug Screening Assays, Antitumor; Humans; Microtubules; Models, Molecular; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |
Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT.
Topics: Apoptosis; Camphanes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2018 |